Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by R. Wang
Total Records ( 4 ) for R. Wang
  J Huang , J Gao , X Lv , G Li , D Hao , X Yao , L Zhou , D Liu and R. Wang

Glioma-specific transcription of tumor-killing genes has been exploited as a promising gene therapeutic modality in glioma patients. Musashi1 (Msi1) and GFAP gene promoters are both cancer-specific promoters. Optimized HIF-binding site (optHBS) sequence was newly found as efficient as EPO HREs used as enhancer in cancer gene therapy. We constructed 4optHBS-Msi1/GFAP promoters and tested their ability to mediate BAX expression to induce apoptosis in glioma cell lines. Our results demonstrated that 4optHBS-Msi1/GFAP promoters are apparently strong and glioma-selective promoters with potential application in targeted glioma gene therapy, and 4optHBS-Msi1/GFAP-BAX are valuable tools for glioma gene therapy.

  Y. Amer , R. Wang and L.D. Abdullatif
  This study discusses the use of green energy and new materials for ship building. We investigate the issue of lowering ship fuel consumption through using high steel plates instead of normal steel plates, propose the use of ‘green fuels’ (gas fuels) as a source of inboard power and discuss the possible utilization of solar energy and wind power for support engine fuel and power usage on vessels.
  Y He , Y Li , Z Peng , H Yu , X Zhang , L Chen , Q Ji , W Chen and R. Wang

A prominent feature of the rodent Muc3 SEA module is the precursor cleavage event that segregates the O-glycosylated N-terminal fragment and transmembrane domain into the noncovalently attached heterodimer. There are seven potential N-glycosylation sites that occur in a cluster in the SEA module of Muc3. However, it is unknown if these sites are modified or what the function of these N-glycans may be in the SEA module. Our data show that the proteolytic cleavage of the rodent Muc3 SEA module was partially prevented by treatment with tunicamycin, an inhibitor of N-glycosylation. Each single mutant of the seven N-glycosylation sites (N1A, N2A, N3A, N4A, N5A, N6A, and N7A) and multiple mutants, including double (N34A) and triple (N345A) mutants, and mutants with four (N3457A), five (N34567A), six (N134567A and N234567A), seven (N1234567A) mutations, confirmed that all seven of these potential sites are N-glycosylated simultaneously. The proteolytic cleavage of the SEA module was not affected when it lacked only one, two, or three N-glycans, but was partially inhibited when lacking four, five, and six N-glycans. In all, 2%, 48%, 85%, and 73% of the products from N3457A, N34567A, N134567A, and N234567A transfectants, respectively, remained uncleaved. The proteolytic cleavage was completely prevented in the N1234567A transfectant, which eliminated all seven N-glycans in the SEA module. The interaction of the heterodimer was independent of the N-glycans within the rodent Muc3 SEA module. Thus, the N-glycosylation pattern constituted a control point for the modulation of the proteolytic cleavage of the SEA module.

  Z. Zhang , C.Y. Zhang , J.P. Guo , L.X. Zhu , X.Y. Luo , R. Wang and Y.H. Liu
  The systemic bioavailability and lung tissue distribution of valnemulin were investigated in swine. About 65 pigs received 10 mg kg-1 body weight of valnemulin by either intravenous (i.v.) or oral (p.o.) route in two studies: study A (10 pigs, i.v. or p.o.) and study B (55 pigs, p.o.). The plasma and lung tissue concentration of the drug were determined by a validated HPLC-MS/MS method. Plasma concentration-time data after i.v. administration (10 mg kg-1 b.w.) were best described by a two-compartment open model. The pharmacokinetic parameters were elimination rate (ke) 0.95±0.17 h-1, the maximum concentrations 4.63±0.66 μg mL-1, area under the plasma concentration-time curve (AUCinf) 5.30±0.37 (h*μg) mL-1. On the other hand, A one-compartment model with a 1st order absorption rate was best fitted to the plasma concentration-time curve of valnemulin after oral administration (10 mg kg-1 b.w.) and the absorption rate (ka) was 0.34±0.03 h-1, the elimination rate (ke) was 1.05±0.19 h-1, the maximum concentration was 0.59±0.08 μg mL-1 at 1.98±0.21 h (tmax), the mean p.o. bioavailability (F) was 57.43%. Following p.o. administration, a mean valnemulin concentration of 0.14 μg g-1 was detected in lung tissue at 36 h postdosing. The lung AUCinf (410.16 h*μg g-1) was 77.39 times higher than the corresponding plasma AUCinf (5.30 h*μg g-1). The apparent elimination half-time for valnemulin in lung was 3.57 h. The advisable bioavailability and extensive distribution to lung tissue following a single dose of valnemulin may be desirable pharmacokinetic attributes for an antimicrobial drug used for the treatment and prevention of respiratory disease in swine.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility